REFERENCES
1. Abdou R, Baredes S. Population-based results in the management of sinonasal and ventral skull base malignancies. Otolaryngol Clin North Am 2017;50:481-97.
2. Sharma RK, Irace AL, Schlosser RJ, et al. Conditional and overall disease-specific survival in patients with paranasal sinus and nasal cavity cancer: improved outcomes in the endoscopic era. Am J Rhinol Allergy 2022;36:57-64.
3. Mirghani H, Mortuaire G, Armas GL, et al. Sinonasal cancer: analysis of oncological failures in 156 consecutive cases. Head Neck 2014;36:667-74.
4. Li X, Li J, Di B, et al. [Recurrence and surgical salvage of sinonasal squamous cell carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2013;48:186-90.
5. Bossi P, Hermsen M, Lechner M, Franchi A. Precision medicine in rare tumors and the need for multicenter trials and international collaboratives: sinonasal cancer as paradigm. Oral Oncol 2020;109:104737.
6. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB. Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck 2002;24:821-9.
7. Harvey RJ, Pitzer G, Nissman DB, et al. PET/CT in the assessment of previously treated skull base malignancies. Head Neck 2010;32:76-84.
8. de Visscher AVM, Manni JJ. Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity. Does it make sense? Arch Otolaryngol Head Neck Surg 1994;120:934-9.
9. Dutta R, Dubal PM, Svider PF, Liu JK, Baredes S, Eloy JA. Sinonasal malignancies: a population-based analysis of site-specific incidence and survival. Laryngoscope 2015;125:2491-7.
10. Porceddu S, Martin J, Shanker G, et al. Paranasal sinus tumors: Peter MacCallum Cancer Institute experience. Head Neck 2004;26:322-30.
11. Suárez C, Ferlito A, Lund VJ, et al. Management of the orbit in malignant sinonasal tumors. Head Neck 2008;30:242-50.
12. Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020;18:873-98.
13. Workman AD, Palmer JN, Adappa ND. Posttreatment surveillance for sinonasal malignancy. Curr Opin Otolaryngol Head Neck Surg 2017;25:86-92.
14. Nyquist GG, Patel PN, Vimawala S, et al. Surgery with post-operative endoscopy improves recurrence detection in sinonasal malignancies. Ann Otol Rhinol Laryngol 2022;131:140-6.
15. Khalili S, Worrall DM, Brooks S, et al. Endoscopy versus imaging: analysis of surveillance methods in sinonasal malignancy. Head Neck 2016;38:1229-33.
16. Zocchi J, Pietrobon G, Campomagnani I, et al. The role of a post therapeutic surveillance program for sinonasal malignancies: analysis of 417 patients. Head Neck 2020;42:963-73.
17. Schwartz JS, Brooks SG, Stubbs V, et al. Temporal patterns of 18F-fluorodeoxyglucose positron emission tomography/computed tomography sinonasal uptake after treatment of sinonasal malignancy. Int Forum Allergy Rhinol 2016;6:1301-7.
18. Chao SS, Loh KS, Tan LKS. Modalities of surveillance in treated nasopharyngeal cancer. Otolaryngol Head Neck Surg 2003;129:61-4.
19. Thawani R, Kim MS, Arastu A, et al. The contemporary management of cancers of the sinonasal tract in adults. CA Cancer J Clin 2023;73:72-112.
20. Guevara-Canales JO, Gutiérrez-Morales MM, Sacsaquispe-Contreras SJS, Sánchez-Lihón J, Morales-Vadillo R. Malignant melanoma of the oral cavity. Review of the literature and experience in a Peruvian Population. Med Oral Patol Oral Cir Bucal 2012;17:e206-11.
21. Maroldi R, Ravanelli M, Farina D, et al. Post-treatment evaluation of paranasal sinuses after treatment of sinonasal neoplasms. Neuroimaging Clin N Am 2015;25:667-85.
22. Kubota K, Yokoyama J, Yamaguchi K, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 2004;31:590-5.
23. Lund VJ, Stammberger H, Nicolai P, et al. European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. Rhinol Suppl 2010;22:1-143.
24. Loevner LA, Sonners AI. Imaging of neoplasms of the paranasal sinuses. Magn Reson Imaging Clin N Am 2002;10:467-93.
25. Ng SH, Liu HM, Ko SF, Hao SP, Chong VFH. Posttreatment imaging of the nasopharynx. Eur J Radiol 2002;44:82-95.
26. Ahmad S, Le CH, Chiu AG, Chang EH. Incidence of intracranial radiation necrosis following postoperative radiation therapy for sinonasal malignancies. Laryngoscope 2016;126:2445-50.
27. Oysu AS, Ayanoglu E, Kodalli N, Oysu C, Uneri C, Erzen C. Dynamic contrast-enhanced MRI in the differentiation of posttreatment fibrosis from recurrent carcinoma of the head and neck. Clin Imaging 2005;29:307-12.
28. Tangyoosuk T, Lertbutsayanukul C, Jittapiromsak N. Utility of diffusion-weighted magnetic resonance imaging in predicting the treatment response of nasopharyngeal carcinoma. Neuroradiol J 2022;35:477-85.
29. Galbán CJ, Mukherji SK, Chenevert TL, et al. A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol 2009;2:184-90.
30. Vandecaveye V, Dirix P, De Keyzer F, et al. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol 2010;20:1703-14.
31. Kawaguchi M, Kato H, Tomita H, et al. Imaging characteristics of malignant sinonasal tumors. J Clin Med 2017;6:116.
32. Bair RJ, Chick JF, Chauhan NR, French C, Madan R. Demystifying NUT midline carcinoma: radiologic and pathologic correlations of an aggressive malignancy. AJR Am J Roentgenol 2014;203:W391-9.
33. de González AB, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009;169:2071-7.
34. Brenner DJ, Hall EJ. Computed tomography - an increasing source of radiation exposure. N Engl J Med 2007;357:2277-84.
35. Lee JC, Kim JS, Lee JH, et al. F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma. Oral Oncol 2007;43:686-92.
36. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of
37. Villar R, Ramos B, Acosta M, Haro JJ, Gómez A. Recurrent adenocarcinoma of the sinonasal tract. Oral Maxillofac Surg 2013;17:155-8.
38. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.
39. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med 1997;38:280-7.
40. Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50:24-9.
41. Workman AD, Glicksman JT, Parasher AK, et al. 18FDG PET/CT in routine surveillance of asymptomatic patients following treatment of sinonasal neoplasms. Otolaryngol Head Neck Surg 2017;157:1068-74.
42. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210-22.
43. Keski-Säntti H, Mustonen T, Schildt J, Saarilahti K, Mäkitie AA. FDG-PET/CT in the assessment of treatment response after oncologic treatment of head and neck squamous cell carcinoma. Clin Med Insights Ear Nose Throat 2014;7:25-9.
44. Gupta T, Master Z, Kannan S, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011;38:2083-95.
45. Gil Z, Even-Sapir E, Margalit N, Fliss DM. Integrated PET/CT system for staging and surveillance of skull base tumors. Head Neck 2007;29:537-45.
46. Abu-Ghanem S, Yafit D, Ghanayem M, Abergel A, Yehuda M, Fliss DM. Utility of first positron emission tomography-computed tomography scan as a prognostic tool following treatment of sinonasal and skull base malignancies. Head Neck 2019;41:701-6.
47. Ozturk K, Gencturk M, Caicedo-Granados E, Li F, Cayci Z. Performance of whole-body 18F-FDG PET/CT as a posttreatment surveillance tool for sinonasal malignancies. Eur Arch Otorhinolaryngol 2019;276:847-55.
48. Akay S, Pollard JH, Saad Eddin A, et al. PET/CT imaging in treatment planning and surveillance of sinonasal neoplasms. Cancers 2023;15:3759.
49. Patel TD, Vazquez A, Dubal PM, Baredes S, Liu JK, Eloy JA. Sinonasal neuroendocrine carcinoma: a population-based analysis of incidence and survival. Int Forum Allergy Rhinol 2015;5:448-53.
50. van der Laan TP, Iepsma R, Witjes MJH, van der Laan BFAM, Plaat BEC, Halmos GB. Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: the importance of differentiation grade in determining treatment strategy. Oral Oncol 2016;63:1-9.
51. Liu KY, Goldrich DY, Ninan SJ, et al. The value of 68Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: a case series. Head Neck 2021;43:E30-40.
52. Roytman M, Tassler AB, Kacker A, et al. [68Ga]-DOTATATE PET/CT and PET/MRI in the diagnosis and management of esthesioneuroblastoma: illustrative cases. J Neurosurg Case Lessons 2021;1:CASE2058.
53. Amit M, Tam S, Abdelmeguid AS, et al. Patterns of treatment failure in patients with sinonasal mucosal melanoma. Ann Surg Oncol 2018;25:1723-9.
54. Tzelnick S, Levin EG, Yacobi D, Mizrachi A, Popovtzer A, Soudry E. Recurrence patterns and efficacy of surveillance modalities for sinonasal malignancies. Am J Rhinol Allergy 2022;36:473-9.
56. Wong KF, Chan JKC, Cheung MMC, So JCC. Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Am J Clin Pathol 2001;115:266-70.
57. Wang Y, Xie L, Tian R, et al. PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma. J Cancer Res Clin Oncol 2019;145:2529-39.
58. Nowak B, Di Martino E, Jänicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999;38:312-8.
59. Ramsay HA, Kairemo KJA, Jekunen AP. Somatostatin receptor imaging of olfactory neuroblastoma. J Laryngol Otol 1996;110:1161-3.
60. Bishop JA, Ogawa T, Stelow EB, et al. Human papillomavirus-related carcinoma with adenoid cystic-like features: a peculiar variant of head and neck cancer restricted to the sinonasal tract. Am J Surg Pathol 2013;37:836-44.
61. Zupancic M, Näsman A. Human papillomavirus-related multiphenotypic sinonasal carcinoma-an even broader tumor entity? Viruses 2021;13:1861.
62. Chang Sing Pang KJW, Mur T, Collins L, Rao SR, Faden DL. Human papillomavirus in sinonasal squamous cell carcinoma: a systematic review and meta-analysis. Cancers 2020;13:45.
63. Naegele S, Efthymiou V, Das D, et al. Detection and monitoring of circulating tumor HPV DNA in HPV-associated sinonasal and nasopharyngeal cancers. JAMA Otolaryngol Head Neck Surg 2023;149:179-81.
64. Huang SH, Jacinto JCK, O’Sullivan B, et al. Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal carcinoma in a North American cohort. Cancer 2022;128:2908-21.
65. Lewis JS Jr, Beadle B, Bishop JA, et al. Human papillomavirus testing in head and neck carcinomas: guideline from the College of American Pathologists. Arch Pathol Lab Med 2018;142:559-97.
66. Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol 2016;17:389-400.
67. Au WY, Kim SJ, Yiu HHY, et al. Clinicopathological features and outcome of late relapses of natural killer cell lymphomas 10-29 years after initial remission. Am J Hematol 2010;85:362-3.
68. Kim SJ, Park Y, Kim BS, Kim I, Ko YH, Kim WS. Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype? Korean J Hematol 2012;47:202-6.
69. Kommalapati A, Tella SH, Ganti AK, Armitage JO. Natural killer/T-cell neoplasms: analysis of incidence, patient characteristics, and survival outcomes in the United States. Clin Lymphoma Myeloma Leuk 2018;18:475-9.
70. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2001;2:683-90.
